Influence of gold marker for magnetic resonance imaging during prostate radiotherapy

• Autorzy: Tanaka O. , Komeda H. , Hirose S. , Taniguchi T. , Ono K. , Yama E. , Matsuo M.

Identyfikatory

DOI

10.2478/pjmpe-2018-0013

• Języki publikacji: EN

Abstrakty

EN

Gold markers (GM) are increasingly used for CT and MRI registration during in intensity-modulated radiation therapy for prostate cancer. Additionally, diffusion-weighted imaging has been adopted to measure the effects of radiotherapy for prostate cancer, similar to tests of blood prostate-specific antigen levels. As diffusion-weighted imaging (DWI) is often affected by a magnetic component, we evaluated the influence of GM on the Diffusion weighted images in three cases. We found that the size range of signal void of GM in MRI was 2–5 mm. We conclude that a GM would not affect the quality of DWI in daily practice.

Słowa kluczowe

EN

prostate cancer; radiotherapy; MRI; fiducial marker; diffusion-weighted

• Wydawca: Polskie Towarzystwo Fizyki Medycznej ; De Gruyter
• Czasopismo: Polish Journal of Medical Physics and Engineering
• Rocznik: 2018
• Tom: Vol. 24, Iss. 3
• Strony: 99--101
• Opis fizyczny: Bibliogr. 8 poz., rys.

Twórcy

autor

Tanaka O.

• Department of Radiation Oncology, Murakimi Memorial Hospital, Gifu, Japan

autor

Komeda H.

• Department of Urology, Gifu Municipal Hospital, Gifu, Japan

autor

Hirose S.

• Division of Radiation Service, Gifu Municipal Hospital, Gifu, Japan

autor

Taniguchi T.

• Department of Radiation Oncology, Murakimi Memorial Hospital, Gifu, Japan

autor

Ono K.

• Department of Radiation Oncology, Murakimi Memorial Hospital, Gifu, Japan

autor

Yama E.

• Division of Radiation Service, Gifu Municipal Hospital, Gifu, Japan

autor

Matsuo M.

• Department of Radiology, Gifu University School of Medicine, Gifu, Japan

Bibliografia

• [1] Yamaguchi H, Hori M, Suzuki O, et al. Clinical Significance of the Apparent Diffusion Coefficient Ratio in Prostate Cancer Treatment with Intensity-modulated Radiotherapy Anticancer Res. 2016;36(12):6551-6556.
• [2] Qi WX, Zhang Q, Li P, et al. The predictive role of ADC values in prostate cancer patients treated with carbon-ion radiotherapy: initial clinical experience at Shanghai Proton and Heavy Ion Center (SPHIC). J Cancer Res Clin Oncol. 2016;142(6):1361-1367.
• [3] Casares-Magaz O, van der Heide UA, Rørvik J, et al. A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps. Radiother Oncol. 2016;119(1):111-116.
• [4] Iannelli G, Caivano R, Rago L, et al. Diffusion-weighted magnetic resonance imaging in patients with prostate cancer treated with radiotherapy. Tumori. 2016;102(1):71-76.
• [5] Decker G, Mürtz P, Gieseke J, et al. Intensity-modulated radiotherapy of the prostate: dynamic ADC monitoring by DWI at 3.0 T. Radiother Oncol. 2014;113(1):115-120.
• [6] Morgan VA, Riches SF, Giles S, et al. Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol. 2012;198(3):596-602.
• [7] Park SY, Kim CK, Park BK, et al. Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):749-755.
• [8] Song I, Kim CK, Park BK, Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol. 2010;194(6):477-482.